-transparent.png){kind=logo}
We investigated the responses of patients with malignant histiocytosis (MH) to the treatment of epotoside-based regimen. Of 11 evaluable cases, 9 (81.8%) achieved complete remission and 1 partial remission. 7 complete remission cases (77.7%) received only one therapeutic course. The side effects were mild and well-tolerated. We conclude that etoposide-containing regimen is highly effective and can be used as first-line treatment for MH and is worthy of further study.
Related Publications
F R Lin, and
E G Yao
January 1979,
Acta haematologica,
F R Lin, and
E G Yao
September 1976,
Cancer,
F R Lin, and
E G Yao
November 1990,
Gynecologic oncology,
F R Lin, and
E G Yao
December 1990,
Japanese journal of clinical oncology,
F R Lin, and
E G Yao
September 1983,
Cancer treatment reviews,
F R Lin, and
E G Yao
January 1978,
Medical and pediatric oncology,
F R Lin, and
E G Yao
January 1977,
Medical and pediatric oncology,
F R Lin, and
E G Yao
May 1996,
Zhonghua zhong liu za zhi [Chinese journal of oncology],
F R Lin, and
E G Yao
January 1986,
The American journal of pediatric hematology/oncology,
F R Lin, and
E G Yao
December 1992,
Seminars in oncology,
